Lung cancer is the most common cause of cancer death in developed countries. The
prognosis is poor, with less than 15% of patients surviving 5 years after diagnosis. The poor …

Lung cancer, like many other epithelial malignancies, is thought to be the outcome of
genetic and epigenetic changes that result in a constellation of phenotypic abnormalities in …

Purpose To review recent advances in pathology and computed tomography (CT) of lung
adenocarcinoma and bronchioloalveolar carcinoma (BAC). Methods A pathology/CT review …

… Immunohistochemistry assays were scored jointly by two authors (WA Franklin and FR
Hirsch); blinded to clinical, FISH, and EGFR mutation results; if discrepancies occurred, a …

Purpose: The epidermal growth factor receptor (EGFR) is frequently overexpressed in non–small-cell
lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic …

Importance Targeting oncogenic drivers (genomic alterations critical to cancer development
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …

Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest
dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not every …

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib
with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer. We …

Smoking is a common risk factor for many diseases 1 . We conducted genome-wide
association meta-analyses for the number of cigarettes smoked per day (CPD) in smokers (n = …

IgA nephropathy has a variable course and leads to renal failure in a substantial number of
cases. In an attempt to identify prognostic indicators in this disease, we evaluated the clinical …